• Policy
• Will RWD-based reimb agreements be more beneficial?
• by Lee, Tak-Sun Aug 29, 2024 04:31am

• Opinion
• [Reporter’s View]Support domestic COVID-19 drugs
• by Lee, Hye-Kyung Aug 28, 2024 05:52am

• Company
• "Switching of atopic dermatitis treatments not yet allowed"
• by Hwang, Byung-woo Aug 28, 2024 05:52am

• Policy
• Price of 17 items cut 30% during Type C PVA negotiations
• by Lee, Tak-Sun Aug 28, 2024 05:52am

• Company
• K-made Leclaza monotherapy to be showcased at global meeting
• by Son, Hyung-Min Aug 28, 2024 05:52am

• Policy
• MFDS to review side effects relief imposed on companies
• by Lee, Jeong-Hwan Aug 28, 2024 05:52am

• Company
• Challenges in the evolving lung cancer treatment landscape
• by Son, Hyung-Min Aug 28, 2024 05:51am

• Company
• Value of new drugs should be evaluated based on efficacy
• by Hwang, Byung-woo Aug 27, 2024 05:50am

• Company
• K-similars won record number of U.S.·Europe nods this year
• by Chon, Seung-Hyun Aug 27, 2024 05:50am

• Policy
• SK Chemicals strengthens migraine drug lineup with Suvexx
• by Lee, Tak-Sun Aug 27, 2024 05:50am